Skip to main content

Table 5 Possibly or probably drug-related adverse events

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Adverse event Placebo NEPA200/0.5 NEPA600/1.5 Moxifloxacin
Number of subjects (%) (N = 50) (N = 49) (N = 49) (N = 49)
Cardiac disorders     
 Palpitations 0 0 1 (2.0) 0
Gastrointestinal disorders     
 Abdominal pain upper 0 2 (4.1) 0 0
 Constipation 0 3 (6.1) 2 (4.1) 0
 Dry mouth 1 (2.0) 0 0 0
 Dyspepsia 1 (2.0) 0 0 0
 Flatulence 1 (2.0) 0 0 0
 Nausea 0 0 0 1 (2.0)
General disorders and administration-site conditions     
 Fatigue 0 1 (2.0) 0 1 (2.0)
 Thirst 0 0 0 1 (2.0)
Musculoskeletal and connective tissue disorders     
 Muscle twitching 1 (2.0) 0 0 0
 Pain in extremity 0 0 1 (2.0) 0
 Sensation of heaviness 1 (2.0) 0 0 0
Nervous system disorders     
 Dizziness 1 (2.0) 0 1 (2.0) 3 (6.1)
 Headache 5 (10.0) 2 (4.1) 5 (10.2) 2 (4.1)
 Somnolence 0 0 1 (2.0) 0
Psychiatric disorders     
 Anxiety 0 0 1 (2.0) 0
 Euphoric mood 0 0 1 (2.0) 0
Total 9 (18.0) 8 (16.3) 10 (20.4) 8 (16.3)
  1. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  2. NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
  3. Percentages are based on N.